Literature DB >> 9708626

Undetectable serum prostate-specific antigen associated with metastatic prostate cancer: a case report and review of the literature.

A A Safa1, D M Reese, D M Carter, J Phillipson, R Smith, S Dougherty.   

Abstract

A 63-year-old man, who had undergone prostatectomy for prostate cancer that was positive for prostate-specific antigen (PSA) was examined and found to have metastatic disease, proven radiologically and pathologically, but with an undetectable PSA and highly elevated prostatic acid phosphatase (PAP). Prostatic acid phosphatase levels fell in response to chemotherapy but his clinical status continued to deteriorate. A review of the literature is presented and several possible explanations for PSA remaining undetectable in these situations are discussed. The authors conclude that although PSA can be used to monitor the majority of patients postprostatectomy, physicians may still need to rely on clinical suspicion, serum PAP, and bone scan for the detection of recurrent disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9708626     DOI: 10.1097/00000421-199808000-00001

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  4 in total

1.  Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report.

Authors:  Chiachien Jake Wang; James Ying; Payal Kapur; Bryan Wohlfeld; Claus Roehrborn; Dong W Nathan Kim
Journal:  Oncol Lett       Date:  2015-11-18       Impact factor: 2.967

2.  Role of Imaging in Prostate Cancer.

Authors:  Hossein Jadvar; Abass Alavi
Journal:  PET Clin       Date:  2009-04-01

3.  Inappropriate treatment of prostate cancer caused by heterophilic antibody interference.

Authors:  Nicolas Henry; Phillipe Sebe; Olivier Cussenot
Journal:  Nat Clin Pract Urol       Date:  2009-03

Review 4.  Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET.

Authors:  Hossein Jadvar
Journal:  Nat Rev Urol       Date:  2009-05-12       Impact factor: 14.432

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.